Citadel Advisors LLC Takes Position in Context Therapeutics Inc. (NASDAQ:CNTX)

Citadel Advisors LLC bought a new stake in Context Therapeutics Inc. (NASDAQ:CNTX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 29,900 shares of the company’s stock, valued at approximately $31,000.

Several other large investors have also modified their holdings of the stock. Marshall Wace LLP purchased a new stake in Context Therapeutics in the 4th quarter valued at $213,000. Renaissance Technologies LLC raised its position in Context Therapeutics by 412.8% in the 4th quarter. Renaissance Technologies LLC now owns 338,435 shares of the company’s stock valued at $355,000 after purchasing an additional 272,435 shares during the last quarter. Geode Capital Management LLC raised its position in Context Therapeutics by 9.2% in the 4th quarter. Geode Capital Management LLC now owns 628,729 shares of the company’s stock valued at $661,000 after purchasing an additional 52,830 shares during the last quarter. Jane Street Group LLC purchased a new stake in Context Therapeutics in the 4th quarter valued at $29,000. Finally, Allostery Investments LP purchased a new stake in Context Therapeutics in the 4th quarter valued at $998,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Stock Performance

Shares of Context Therapeutics stock opened at $0.65 on Friday. The company has a market cap of $58.54 million, a P/E ratio of -0.72 and a beta of 1.86. Context Therapeutics Inc. has a one year low of $0.49 and a one year high of $2.75. The firm has a fifty day moving average of $0.75 and a two-hundred day moving average of $0.91.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). As a group, equities analysts predict that Context Therapeutics Inc. will post -0.51 earnings per share for the current year.

Wall Street Analyst Weigh In

CNTX has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Context Therapeutics in a research report on Friday, March 21st. William Blair reiterated an “outperform” rating on shares of Context Therapeutics in a research report on Tuesday, April 29th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a research report on Thursday, May 8th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $6.00.

Insiders Place Their Bets

In other news, CEO Martin A. Lehr acquired 100,000 shares of the business’s stock in a transaction on Monday, June 9th. The stock was bought at an average price of $0.70 per share, for a total transaction of $70,000.00. Following the transaction, the chief executive officer now owns 920,190 shares in the company, valued at $644,133. This represents a 12.19% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Jennifer Lynn Minai-Azary acquired 40,010 shares of the business’s stock in a transaction on Friday, June 6th. The shares were purchased at an average price of $0.64 per share, with a total value of $25,606.40. Following the transaction, the chief financial officer now owns 80,010 shares in the company, valued at $51,206.40. The trade was a 100.03% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders bought 160,010 shares of company stock worth $107,206. 2.80% of the stock is owned by insiders.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.